Several studies demonstrate reduced levels of CCL5/CCR4, CCL22, CCL21, and CCR6 in vitiligo skin, which could explain the failure of circulating Tregs to localize to the skin [126,129,134,135,136,137], thus suggesting that the modulating expression of these chemokines may be potential therapeutic targets in vitiligo. The gene discussed is CCL21; the disease is vitiligo.